...
avir-img

Atea Pharmaceuticals Inc, Common Stock

AVIR

NSQ

$3.46

+$0.16

(4.85%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$278.73M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.17
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.88 L
$4.6 H
$3.46

About Atea Pharmaceuticals Inc, Common Stock

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameAVIRSectorS&P500
1-Week Return9.49%2.3%1.73%
1-Month Return1.17%-1.77%3.44%
3-Month Return-9.9%-6.07%7.02%
6-Month Return-4.16%2.45%13.38%
1-Year Return20.14%12.17%32.25%
3-Year Return-55.87%10.46%29.27%
5-Year Return-88.6%46.4%90.61%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-48.63M351.37M192.18M-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":13.84,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":54.69,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue17.00K19.00K29.00K260.00K70.09M[{"date":"2019-12-31","value":0.02,"profit":true},{"date":"2020-12-31","value":0.03,"profit":true},{"date":"2021-12-31","value":0.04,"profit":true},{"date":"2022-12-31","value":0.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(17.00K)48.61M351.37M(260.00K)(70.09M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":13.84,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.07,"profit":false},{"date":"2023-12-31","value":-19.95,"profit":false}]
Gross Margin-99.96%100.00%(0.14%)-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":99.96,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.14,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses14.61M59.66M212.99M130.65M94.07M[{"date":"2019-12-31","value":6.86,"profit":true},{"date":"2020-12-31","value":28.01,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":61.34,"profit":true},{"date":"2023-12-31","value":44.17,"profit":true}]
Operating Income(14.61M)(11.03M)138.38M(130.65M)(164.16M)[{"date":"2019-12-31","value":-10.56,"profit":false},{"date":"2020-12-31","value":-7.97,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-94.42,"profit":false},{"date":"2023-12-31","value":-118.63,"profit":false}]
Total Non-Operating Income/Expense1.15M166.00K426.00K22.30M58.45M[{"date":"2019-12-31","value":1.96,"profit":true},{"date":"2020-12-31","value":0.28,"profit":true},{"date":"2021-12-31","value":0.73,"profit":true},{"date":"2022-12-31","value":38.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(14.03M)(10.95M)138.59M(119.50M)(134.94M)[{"date":"2019-12-31","value":-10.13,"profit":false},{"date":"2020-12-31","value":-7.9,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-86.22,"profit":false},{"date":"2023-12-31","value":-97.36,"profit":false}]
Income Taxes(574.00K)(83.00K)17.40M(3.59M)1.02M[{"date":"2019-12-31","value":-3.3,"profit":false},{"date":"2020-12-31","value":-0.48,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-20.63,"profit":false},{"date":"2023-12-31","value":5.85,"profit":true}]
Income After Taxes(13.46M)(10.86M)121.19M(115.91M)(135.96M)[{"date":"2019-12-31","value":-11.11,"profit":false},{"date":"2020-12-31","value":-8.96,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-95.64,"profit":false},{"date":"2023-12-31","value":-112.18,"profit":false}]
Income From Continuous Operations(14.03M)(10.95M)121.19M(115.91M)(135.96M)[{"date":"2019-12-31","value":-11.58,"profit":false},{"date":"2020-12-31","value":-9.03,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-95.64,"profit":false},{"date":"2023-12-31","value":-112.18,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(13.46M)(10.86M)121.19M(115.91M)(135.96M)[{"date":"2019-12-31","value":-11.11,"profit":false},{"date":"2020-12-31","value":-8.96,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-95.64,"profit":false},{"date":"2023-12-31","value":-112.18,"profit":false}]
EPS (Diluted)-(0.97)1.36(1.40)(1.64)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-71.32,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-102.94,"profit":false},{"date":"2023-12-31","value":-120.59,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AVIR
Cash Ratio 19.17
Current Ratio 19.33

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AVIR
ROA (LTM) -14.25%
ROE (LTM) -33.46%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AVIR
Debt Ratio Lower is generally better. Negative is bad. 0.07
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.93

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AVIR
Trailing PE NM
Forward PE NM
P/S (TTM) 1.90
P/B 0.61
Price/FCF NM
EV/R 58.97
EV/Ebitda NM

FAQs

What is Atea Pharmaceuticals Inc share price today?

Atea Pharmaceuticals Inc (AVIR) share price today is $3.46

Can Indians buy Atea Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Atea Pharmaceuticals Inc (AVIR) on Vested. To buy Atea Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AVIR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Atea Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Atea Pharmaceuticals Inc (AVIR) via the Vested app. You can start investing in Atea Pharmaceuticals Inc (AVIR) with a minimum investment of $1.

How to invest in Atea Pharmaceuticals Inc shares from India?

You can invest in shares of Atea Pharmaceuticals Inc (AVIR) via Vested in three simple steps:

  • Click on Sign Up or Invest in AVIR stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Atea Pharmaceuticals Inc shares
What is Atea Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Atea Pharmaceuticals Inc (AVIR) is $4.6. The 52-week low price of Atea Pharmaceuticals Inc (AVIR) is $2.88.

What is Atea Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Atea Pharmaceuticals Inc (AVIR) is

What is Atea Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Atea Pharmaceuticals Inc (AVIR) is 0.61

What is Atea Pharmaceuticals Inc dividend yield?

The dividend yield of Atea Pharmaceuticals Inc (AVIR) is 0.00%

What is the Market Cap of Atea Pharmaceuticals Inc?

The market capitalization of Atea Pharmaceuticals Inc (AVIR) is $278.73M

What is Atea Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Atea Pharmaceuticals Inc is AVIR

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top